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Background: This report describes a method for the generation of global gene expression profiles from low
frequent B-cell subsets by using fluorescence-activated cell sorting and RNA amplification. However, some of the
differentiating compartments involve a low number of cells and therefore it is important to optimize and validate
each step in the procedure.
Methods: Normal lymphoid tissues from blood, tonsils, thymus and bone marrow were immunophenotyped by
the 8-colour Euroflow panel using multiparametric flow cytometry. Subsets of B-cells containing cell numbers
ranging from 800 to 33,000 and with frequencies varying between 0.1 and 10 percent were sorted, subjected to
mRNA purification, amplified by the NuGEN protocol and finally analysed by the Affymetrix platform.
Results: Following a step by step strategy, each step in the workflow was validated and the sorting/storage
conditions optimized as described in this report. First, an analysis of four cancer cell lines on Affymetrix arrays, using
either 100 ng RNA labelled with the Ambion standard protocol or 1 ng RNA amplified and labelled by the NuGEN
protocol, revealed a significant correlation of gene expressions (r ≥ 0.9 for all). Comparison of qPCR data in samples
with or without amplification for 8 genes showed that a relative difference between six cell lines was preserved
(r ≥ 0.9). Second, a comparison of cells sorted into PrepProtect, RNAlater or directly into lysis/binding buffer showed
a higher yield of purified mRNA following storage in lysis/binding buffer (p < 0.001). Third, the identity of the B-cell
subsets validated by the cluster of differentiation (CD) membrane profile was highly concordant with the transcriptional
gene expression (p-values <0.001). Finally, in normal bone marrow and tonsil samples, eight evaluated genes were
expressed in accordance with the biology of lymphopoiesis (p-values < 0.001), which enabled the generation of a
gene-specific B-cell atlas.
Conclusion: A description of the implementation and validation of commercially available kits in the laboratory has been
examined. This included steps for cell sorting, cell lysis/stabilization, RNA isolation, RNA concentration and amplification for
microarray analysis. The workflow described in this report will enable the generation of microarray data from minor sorted
B-cell subsets.
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Haematological malignancies are characterised by a con-
tinuous sub-clonal selection that becomes abnormally
and non-homogeneously distributed within individual
tumours. In most cases, malignant transformation and
metastases are clonal since they are derived from single
cells that, at least initially, preserve many features of the
hierarchical structure of the normal tissue of origin. How-
ever, this has not been analysed systematically for malignan-
cies [1-3]. Global gene expression profiling (GEP) and
genetic alterations have already resulted in changes in the
classification of malignant B-cell disorders [4-8], including
identification of the normal cell of origin. Consequently,
highly pure normal subpopulations are essential in order to
investigate the complex cellular and molecular mechanisms
involved in the stepwise B-cell differentiation in normal
and malignant conditions [9-11].
The molecular mechanisms that control B-cell lympho-
poiesis are regulated by the coordinated activity of a group
of so-called master regulatory transcription factors (TF)
[12]. TFs can be divided into those that maintain B-cell
lineage commitment (such as PAX5) and the TFs involved
in the germinal centre (GC) reaction (such as BACH2 and
BCL6), and those that promote and facilitate end-stage dif-
ferentiation, notably IRF4, PRDM1, and XBP1. This ensures
the separation of a range of well-defined subsets including
pre-BI cells, pre-BII cells, immature (I), naive (N), centro-
cytes (CC), centroblasts (CB), memory B-cells (M), plasma-
blasts (PB) and end-stage antibody producing plasma cells
(PC) [13-15].
A limiting factor in studies of B-cell subsets, however,
is that some of the differentiating compartments involve
a low number of cells and it is therefore important to
optimize and validate each step in the procedure for global
GEP of minor B-cell subsets following fluorescence-
activated cell sorting (FACS). In addition, the conventional
labelling kits require an input of 50 – 500 ng of total
RNA, which corresponds to around 105 to 106 cells,
depending on cell type. However, it is practically im-
possible to obtain such numbers from some B-cell sub-
populations as they only constitute between 0.1 and
10% of the lymphoid tissue [16].
Early human B-cell development has been character-
ized by GEP, using FACS purified B-cell subsets in bone
marrow (BM) [17,18]. However, whereas the early B-cell
differentiation has been characterized, the simultaneous
sorting of post-germial centre B-cells in lymphoid tissue
has been explored in less detail. The concept behind
the present project is that a detailed workflow for the
generation of GEP from minor B-cell subsets will allow
us to establish a B-cell specific gene atlas. This will in-
crease our knowledge of the B-cell differentiation and,
ultimately, to use these gene lists in post-GC disease
classification. The aims of the study were to validate andimplement a fast and efficient method for isolation and
generation of GEP from B-cell subsets in peripheral
blood, tonsils, thymus and BM in order to generate a
gene-specific B-cell atlas. The strategy omits an immu-
nomagnetic purification step for B-cell enrichment
before FACS, as often performed [17-20], which is
problematic when low frequent B-cells are sorted.
Methods
Protocol overview
A flow chart of the established protocol and methods
for sorting the B-cell subsets in different tissue [see
Additional file 1].
Impact of amplification
Gene specific amplification determined by qPCR
Total RNA from one million cells was extracted from six
multiple myeloma (MM) cancer cell lines (CCLs) (MOLP-
8, KMS-12-BM, RPMI-8226, OPM-2, LP-1, and KMM-1)
using RNAeasy Plus Micro equipment (QIAGEN, Hilden,
Germany). Genomic DNA was removed using gDNA
Eliminator Spin Columns (QIAGEN, Hilden, Germany).
RNA quality was evaluated with an Agilent 2100 bioanaly-
zer (Agilent Technologies, Inc., Palo Alto, CA) (RIN > 9.8).
Total RNA from each CCL was processed in parallel by
either directly converting 500 ng to cDNA (non-ampli-
fied) with SuperScript III First-Strand Synthesis Supermix
(Invitrogen, Paisley, UK) or by amplifying 5 ng with an
Ovation Pico WTA system (NuGEN Technologies,
Inc., San Carlos, CA), as described by the manufac-
turer. QPCR assays were performed by comparing
amplified cDNA at 25 ng/reaction to non-amplified
cDNA derived from SuperScript III at 25 ng/reac-
tion (total RNA equivalents). Commercially available
Taqman primer probes sets, previously described in the
qPCR Section, were used.
Comparing NuGEN protocol to standard protocol
Total RNA from one million cells of the same four CCLs
KMM-1, OPM-2, U2932_M, and SU-DHL-5 was sub-
jected to the NuGEN protocol or to the standard protocol
from Ambion (Ambion WT Expression kit, Ambion, Inc.,
Austin, TX) following the manufactures recommenda-
tions. The input of total RNA was 1 ng for the NuGEN
protocol whereas the input for the Ambion protocol was
100 ng.
Optimisation of storage buffer
Selection of storage buffer for sorted cells
The storage buffer was examined by sorting 15,000 fresh
naive tonsil cells from a single donor directly into 12
separate tubes containing 450 μl of either lysis/binding
buffer, RNAlater (Ambion, Austin, TX) or PrepProtect.
mRNA was isolated using the μMACS™ technology
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ing isolation on μ Columns and elution with pure water.
This technology is referred to as magnetic bead isolation
(MBI). MBI purification from sorted cells was performed
in triplicates, either directly after cell sorting or after
14 days of storage of cells in the various RNA extraction
buffers at 4°C, -20°C or −80°C. Before purification, all
samples were equilibrated to RT and cells in RNAlater
and PrepProtect was recovered from the storage solution
by a 5 minute centrifugation (RT) at 5000 g and re-
suspended in 450 μl of lysis/binding buffer, following
MBI purification. Elutes were stored at −80°C before
examining the yields with the TaqMan pre-developed
endogenous control assay PPIA (333763 F) by RT-qPCR.
Ethical statement and tissue preparation
All samples were collected following informed consent
in accordance with the research protocol accepted by
the Ethics Committee for the North Denmark Region
(N-20080062MCH). The cells were either FACS sorted
fresh (i.e. samples collected, processed and sorted within
the same day), or vital cryopreserved for storage and
thawed before sorting.
Isolation of cells from tissues
The isolation strategy of all tissues is described in the
following section, including the number of donors (n)
for each tissue and the frequency of sorted cells used
for generating GEP and establishing a B-cell atlas from
different B-cell subsets in tonsils and BM.
Peripheral blood mononuclear cells (PBMNC) (frequency of
sorted cells: 4,500 – 130,000)
PBMNC (n = 6 ) were isolated by diluting the peripheral
blood sample 1:1 in phosphate-buffered saline (PBS)
and placing the sample in a LeucoSep tube (Greiner
Bio-One, Frickenhausen, Germany), according to the
manufacturer’s instructions. The mononuclear cells
(MNCs) were washed once and the red blood cells were
lysed by adding 9 ml of Easylyse (DAKO, Glostrup,
Denmark) to the pellet and incubating the sample for
15 minutes at room temperature (RT). The MNCs were
washed twice in PBS and sorted fresh.
Tonsils (frequency of sorted cells: 5,600 – 20.000)
Tonsils (n = 8) were obtained by routine tonsillectomy as
previously described [9]. In brief, tonsils were placed
on ice until homogenization in cold RPMI medium
1640 (Gibco, Invitrogen, UK) using a Medimachine (cod.
79200, Dako, Glostrup, Denmark) with a 35 μM sterile
medicon. The cell suspension was passed through a
40 μM filter to remove debris and aggregates. The cell
suspension was diluted in PBS before MNCs were iso-
lated using Ficoll-Paque Plus (GE Health Care, Uppsala,Sweden) according to the manufacturer’s instructions.
The cells were vital cryopreserved.
Thymus (frequency of sorted cells: 1,000 – 33,000)
Thymus (n = 7) was obtained from patients undergoing
cardiac surgery and placed on ice immediately after re-
moval and cut into smaller pieces. BM was simultan-
eously obtained from the same patient and processed as
described in the following section. The Thymus tissue
was squeezed and chopped with a tweezer in PBS. The
cells were washed once in PBS and MNCs were purified
using Ficoll-Paque Plus and sorted fresh.
BM (frequency of sorted cells: 800 – 25,000)
BM (n = 7) from sternum was obtained from patients
undergoing cardiac surgery by physical scraping and
scooping of the sternum and placed on ice immediately
after removal. The BM was homogenized in 2 ml PBS
using a syringe. The red blood cells were lysed by adding
20 ml of Easylyse (DAKO, Glostrup, Denmark) and in-
cubating the sample for 45 min at RT. The samples were
washed once in PBS before passing through a 40 μM fil-
ter to remove debris and aggregates and sorted fresh.
Human malignant B-cell lines
CCLs originating from MMMOLP-8, KMS-12-BM, RPMI-
8226, LP-1, OPM-2 and diffuse large B-cell lymphoma
(DLBCL) SU-DHL-5 were purchased from DSMZ
[German Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany], whereas the MM CCL KMM-1
was purchased from JCRB [Japanese Collection of Research
Bioresources Cell Bank, Japan]. DLBCL CCL U2932_M
was generously provided by Jose A Martinez-Climent
[Molecular Oncology Laboratory, University of Navarra
Pamplona, Spain].
Multiparametric flow cytometry
MNCs were washed twice in PBS and in the final wash
2% BSA was added. The cells were stained with a 6–8
colour panel of monoclonal antibodies (mAbs). Isolating
the B-cell subsets from PBMMC, tonsils, thymus and
BM had the following five mAbs in common: CD20
clone 2H7 conjugated with pacific blue (eBioscience,
San Diego, CA), CD45 clone 2D1 conjugated with ane-
monia majano cyan (BD Biosciences, San Jose, CA),
CD10 clone HI10a conjugated with phycoerythrin/cya-
nin7 (BD Biosciences, San Jose, CA), CD27 clone L128
conjugated with Allophycocyanin (BD Biosciences, San
Diego, CA), CD38 clone HIT2 conjugated with Alexa
Flour 700 (ExBio Vestec, Czech Republic). CD19 conju-
gated with PERCPCy5.5 (BD Biosciences, San Diego,
CA) were included in all samples except in tonsils. In
BM, CD34 conjugated with phycoerythrin (BD Biosciences,
San Diego, CA) were included. In tonsils, CD3 clone
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Biosciences, San Jose, CA), CD44 clone IM7 conju-
gated with peridinin chlorophyll protein/cyanin 5.5
(eBiosciences, San Diego, CA), and CXCR4 clone 12G5
conjugated with phycoerythrin (Beckman coulter, Brea,
CA) were included. In thymus, sIgM conjugated with
FITC (DAKO, Carpinteria, US) and sIgG conjugated
with phycoerythrin (SouthernBiotech, Alabama, US)
were included.
CD marker combinations used to distinguish between the
B-cell subsets [see Additional file 1]
Briefly, all cells but tonsils were incubated for 30 minutes
at room temperature (RT) (tonsils on ice) in darkness.
Sorting of B-cell subsets was performed using a FAC-
SAria2 cell sorter (BD Biosciences, San Jose, CA) at RT.
Compensation was automatically calculated by FACS-
Diva software using single-stained control samples with
the mAbs previously listed. Immediately before acquisi-
tion, the cells were filtered through a 35-μm filter (Cell
Stainer, BD Biosciences). The purity of the isolated
B-cell subsets (>90%) was confirmed by sorting approxi-
mately 1,000 cells into PBS and reacquisition of the
sorted B-cell subsets. The cells were sorted into 450 μl of
lysis/binding buffer (Miltenyi Biotech, Bergisch-Gladbach,
Germany), except for the first PBMNC processed, which
were sorted into 1 ml of PrepProtect (Miltenyi Biotech,
Bergisch-Gladbach, Germany). The sorted B-cell subsets
were stored at −20°C.
Global GEP of sorted B-cell subsets
Gene expression analysis of FACS sorted cells was per-
formed using the Gene Chip Human Exon 1.0 ST (Exon)
or the Gene chip HG U133 Plus 2.0 (U133) arrays
(Affymetrix, Santa Clara, CA). In brief, mRNA was iso-
lated by MBI and the eluted mRNA was concentrated
to 5–10 μl by a volume reduction step using a speedVac
Concentrator 5310 (Eppendorf, Hamburg, Germany).
Five μl was used as input for amplification with the
Ovation Pico WTA system (NuGEN Technologies, Inc.,
San Carlos, CA) following the manufacturer’s protocol.
Due to technical challenges, it was not possible to deter-
mine the concentration of mRNA derived from five μl of
elute. Finally, the samples were hybridised to the Exon or
U133 array. This is referred to as the NuGEN protocol.
Reverse transcription and qPCR
Complementary DNA synthesis
Five μl of mRNA from sorted cells or 500 ng of total RNA
from CCLs were used in cDNA synthesis using SuperScript
III First-Strand Synthesis Supermix (Invitrogen, Paisley,
UK). Random hexamers (50 μM) and oligo(dT) (50 μM)
primers were used in a final volume of 20 μl.qPCR
qPCR was performed on a LightCycler 480 II using
the LightCycler 480 Probes Masters PCR mix (Roche
Diagnostics, Hvidovre, Denmark) and Taqman gene
expression assays (Applied Biosystems, Foster City, CA) in
a final reaction volume of 20 μl. Water controls, no-RT
samples, and inter-run calibrator samples were included on
all plates. Commercially available Taqman primer/probe
sets were used (Applied Biosystems, Foster City, CA) for
three endogenous control genes: PPIA [4333763 F],
GAPDH [4333764 F] and TBP [4333769 F], for three tran-
scription factors involved in the late B-cell lymphopoiesis:
IRF4 [Hs01056534_m1], PRDM1 [Hs00153357_m1] and
XBP1 [Hs00231936_m1] and two genes related to the
oncogenesis of MM: MGST1 [Hs00220393_m1] and
WHSC1 aliasMMSET [Hs00983716_m1].
Statistical analysis
All data processing and statistical analysis was per-
formed using Affymetrix GeneChip Command Console
Software (AGCC), Partek Genomics Suite version 6.5
(Partek Inc., St. Louis, MO, USA), built-in Excel macros,
and the statistical software system R, version 2.15.1. For
all tests, p-values below 5% (p < 0.05) were considered
statistically significant.
Gene specific amplification determined by qPCR
For a specific gene, x, the difference in Cq values (dCq)
between two amplified CCLs, 1 and 2, (Cqx,1 –
Cqx,2)amplified, was plotted against the dCq-value for the
same two non-amplified cell lines (Cqx,1 – Cqx,2)non-amplified.
Pearson’s correlation coefficient between the two dCq
values was calculated. A significant positive Pearson’s
correlation coefficient indicates preservation of differen-
tial gene expression after amplification [21]. In addition,
for each gene, the six cell lines were ranked from high to
low expression. This ranking was performed for both the
non-amplified and the amplified cell lines, and compared
using Spearman’s rank correlation. A test for incon-
sistent ranking was carried out by an exact permutation
test.
Selection of storage buffer for sorted cells
The Cq values were analysed by a 2-way analysis of vari-
ance (ANOVA) with the two factors storage buffer at
three levels (Lysis buffer; PrepProtect; RNAlater) and
condition at four levels (Directly; 4°C; -20°C; -80°C).
Data processing and analysis
CEL-files from the two array types U133 and Exon were
generated by AGCC [for results of the initial quality
control analyses, see Additional file 2]. CEL-files were
imported into Partek and RMA normalised. Due to
in-homogenous variance, the difference in expression
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dogenous control genes was tested by a Kruskal-Wallis
one-way analysis of variance. Furthermore, for biological
validation, the expression values of selected genes with
well-known function in each B-cell subset of the BM
were analysed. Significant expressions between func-
tional classes of B-cell subsets were tested by a two-
tailed t-test with unequal variance. Correlations between
two measurements were evaluated throughout by the
Pearson’s correlation coefficient and denoted by an r.
Finally, plots of gene differences versus gene averages,
MA plots, were used to examine the concordance be-
tween methods for generating global GEP.
Concordance between the pre-defined CD marker and array
based transcript expressions
The B-cell subsets were divided into two groups based
on the pre-defined positive or negative CD marker. The
mean and standard deviations were calculated for the
positive and negative groups based on the gene expres-
sion value for the CD marker. Discordance was regis-
tered if a gene expression value for a B-cell subset was
observed in the opposite group as defined by the CD
marker. Fisher’s exact test for 2x2 tables was used to test
for independence between the groupings based on CD
marker and GEP [see Additional file 3].
Freshly sorted samples or cryopreservation before sorting
The ratios of excluded samples were compared for freshly
sorted samples as well as for those cryopreserved before
sorting. Samples were either excluded due to low amplifica-
tion yield or unsatisfactory quality control parameters on
array. The significance between the ratios was tested by a
chi-square test for equality of proportions.
Results
Impact of amplification
Gene specific amplification determined by qPCR
A major concern is the amplification method and how it
affects the ability to maintain the relative amount of the
starting RNA, the so called fidelity of amplification [22].
This was evaluated by comparing the expression of eight
genes, which included the three endogenous control
genes (PPIA, TBP and GAPDH), three transcription fac-
tors involved in the late B-cell lymphopoiesis (XBP1,
IRF4 and PRDM1), and two genes related to oncogenesis
of MM (MGST1 and WHSC1) in six amplified and non-
amplified CCLs [see Additional file 4]. Total RNA from
one million cells was extracted from each of the six
CCLs. The ranks of the selected genes in non-amplified
and amplified CCLs were fairly preserved (p-values =
0.02, 0.10, 0.05, 0.01, 0.07 and 0.03 for CCLs KMM-1,
KMS-12-BM, LP-1, MOLP-8, OPM-2 and RPIM-8226,
respectively). However, a transcript-specific amplificationeffect was noticed, meaning that some transcripts were
amplified with a higher efficiency than others, exempli-
fied in PPIA compared to WHSC1 [see Additional file 5].
We therefore examined whether the relative difference
in gene expression was preserved in the six CCLs after
amplification. For each gene, the difference in delta Cq
between two non-amplified CCLs was plotted against
the delta Cq in the same amplified CCLs with results as
presented in Figure 1A. Pearson’s correlation coefficient
(r = 0.92) indicated a good preservation of the gene-
specific amplification across samples. These results em-
phasise that, when this protocol is to be used to generate
global gene expression data, the expression level of a
specific gene should only be compared across samples
that are all non-amplified or all amplified.
Comparing NuGEN protocol to standard protocol
The NuGEN’s protocol was compared to Ambion’s
protocol, which utilises the most routinely used labelling
method. The Ambion protocol is based on in vitro tran-
scription (IVT) of a cDNA template into complementary
RNA (cRNA), using T7 RNA polymerase [23,24]. The
same total RNA, extracted from one million cells, from
the four CCLs was processed with either Ambion’s or
NuGEN’s protocol, reducing the input amount by a 100
times. Both protocols generated acceptable yields to
target preparation and hybridisation to Exon array,
according to the manufacturer’s recommendations, as
presented in Table 1. The non-specific amplification
products, when amplification was performed without
RNA (negative control), were nearly the same with
14% (5.2 μg) for Ambion and 11% (0.8 μg) for NuGEN.
In addition, we noticed that the present calls were a bit
higher for the Ambion protocol.
The reproducibility between the two protocols was
first examined by the narrow set of previously used
genes [see Additional file 6]. The expression of the
selected genes generated by the NuGEN protocol was
plotted against the expression of the genes generated by
the Ambion protocol as presented in Figure 1B. We ob-
served a high degree of correlation between the two
protocols regarding the expression from the eight genes
(r = 0.950). Next, we measured the reproducibility of the
gene expression on a global scale by generating MA
plots [see Additional file 7]. We observed a Pearson’s
correlation coefficient ranging from r = 0.892 to r = 0.904
for all pair-wise comparisons of protocols, demonstrat-
ing an acceptable reproducibility and robustness of the
NuGEN protocol.
Optimisation of storage buffer
Selection of storage buffer for sorted cells
A priori, the handling procedures were considered im-
portant, including methods for RNA extractions [25-29].
Figure 1 Evaluating the impact of amplification. A: Gene-specific amplification determined by qPCR. Scatter plot comparing dCq for a gene
between two cell lines for non-amplified samples with dCq for the same gene and cell lines after amplification. Pearson’s correlation coefficient is
r = 0.917. Genes included PPIA, TBP, GAPDH, IRF4, PRDM1, XBP1, WHSC1 and MGST1. B: Comparing NuGEN protocol to standard protocol. Scatter
plot comparing the Exon expression values generated by the NuGEN protocol to expression values generated by the Ambion protocol. Genes
included are PPIA, TBP, GAPDH, IRF4, PRDM1, XBP1, WHSC1, and MGST1. The Pearson’s correlation coefficient is r = 0.950.
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tion from flow-sorted cells was MBI [30], which was se-
lected for the present study. A pilot study revealed that
the recovery of relative few cells (50,000-200,000) after
centrifugation varied by up to 50% (Unpublished obser-
vations). Cells sorted in conventional storage buffers
such as PrepProtect or RNAlater include a centrifuga-
tion step in order to re-suspend the cells in lysis buffer.
Therefore, we wanted to test if the lysis/binding buffer
could be used as a storage buffer, thereby omitting the
centrifugation step in the procedure.
The yield of mRNA from 15,000 sorted cells was tested
in three different storage buffers after immediate or post-
poned time to mRNA purification. The mRNA yields, indi-
cated by Cq values, were significantly higher for cells sorted
into lysis/binding buffer compared to PrepProtect (p <
0.001) or RNAlater (p < 0.001), as shown in Figure 2A.
In addition, for cells sorted into lysis/binding buffer,
mRNA purification directly after cell sorting resulted in a
significantly higher yield (p < 0.001) compared to mRNATable 1 Amount of starting material and percent present call
Protocol Sample Starting amount




Negative control 0 ng




Negative control 0 ng
Total RNA from the same four CCLs was either processed with the Ambion or NuGE
times and the amount present calls were calculated with the PLIER algorithm in Exp
total RNA.extraction from cells performed after 14 days of storage at
4°C, -20°C and −80°C.Performance of the protocol
Amplified yield from FACS tonsil B-cell subsets
The technical variation in the protocol, including flow sort-
ing, freezing, purifying mRNA, up-concentrating RNA and
amplifying the samples, was addressed by sorting two B-cell
subsets, namely the N and the PB from tonsils in triplicates
from a single donor. By sorting different numbers of cells
(500, 1,000 and 5,000 PBs and 1,000, 5,000 and 10,000 N
cells), we found that the amplified cDNA yield per cell var-
ied depending on cell type, with PBs providing a higher
yield compared to N cells (Figure 2B). Based on the ampli-
fied cDNA yield, 1,000 PB and 5,000 N was sufficient for
generating global GEP, according to the input requirement
in the protocol. These samples were only intended to be
used to investigate the technical variation in the protocol
and not used to generate global GEP.s on Exon arrays











N protocol. The input amount for the NuGEN protocol was reduced by 100
ression Console (Affymetrix). Negative control is amplification without
Figure 2 Optimization and performance of the protocol. A:
Selection of storage buffer for sorted cells. RNA yield from 15,000 N
tonsil cells. The cells were sorted into different storage reagents and
mRNA was purified with MBI either immediately after cell sorting or
after 14 days of storage at 4°C, -20°C and −80°C. RNA yields were
determined by RT-qPCR targeting PPIA. Mean Cq values were
calculated from triplicate RNA extractions from each storage reagent.
Error bars represent SD (n = 3). B: Amplified cDNA yield from a fixed
number of flow sorted N and PB cells derived from a tonsil. The cells
were sorted in lysis/binding buffer and mRNA was purified with MBI.
Prior to amplification, the mRNA was concentrated by speedVac
centrifugation. The amplified cDNA yield was measured on the
nanodrop. Error bars represent SD of 3 experiments.
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Using the protocol, GEP was successfully established
on a low number of FACS sorted cells in the frequency
of 800–33,000 cells in lysis/binding buffer from diffe-
rent tissues including PBMNC, tonsils, thymus and
BM (Table 2). For PBMNCs, GEP was performed on
both fresh (F) and cryopreserved (C) sorted cells with no
significant difference in the number of excluded samples
(p = 0.991), demonstrating the applicability of the protocol
to cryopreserved material irrespective of B-cell subset
(manuscript in preparation).Concordance between the predefined CD marker and array-
based transcript expressions
A quality control step was included to validate the identity
of the sorted B-cell subsets by correlating the pre-defined
surface expressed CD markers used for FACS of the B-cell
subsets to the CD markers transcript expression levels on
microarray [see Additional file 3]. In summary, there was
a highly significant (p < 0.001) concordant expression of
CD protein markers and transcript expressions. For ex-
ample, in a total of 44 PBMNC samples concordance
was observed for CD20, CD10, CD27, and CD38 gene
expression in 43, 43, 42, and 41 samples respectively
[see Additional file 3: Table S2].
Biological validation
Global GEP data were generated from sorted B-cell sub-
sets in PBMNC and lymphoid tissues. The initial data
analysis was carried out to explore similarities and differ-
ences between samples and to determine whether the
samples could be grouped into distinct B-cell subsets.
The data matrix was subjected to principal component
analysis (PCA) and the results are shown in the
Additional file 8. It is noted that the preBI and II; imma-
ture, naive and memory B-cells; plasmablasts and plasma
cells tended to cluster in separate biological relevant
groups, as expected. In addition, naive and memory
B-cells tended to cluster together, regardless of tissue, as
did the centroblasts and centrocyte populations in
tonsils, regardless of array type. Of note, the tonsil donors
on the Exon and U133 arrays are not identical.
The usefulness of the protocol was examined in the
global GEP data generated from normal BM samples on
the Exon array. This was evaluated by comparing the ex-
pression of eight genes, which included the former eval-
uated endogenous control genes (PPIA and TBP). In
addition, the transcription factors involved in the B-cell
differentiation (PAX5, XBP1, IRF4 and PRDM1) and the
genes RAG1, RAG1, involved in the early B-cell differen-
tiation, were included. Dys-regulation of these genes is
among the most central mediators of malignant trans-
formation. The box plots of eight genes are presented in
Figure 3. As expected, the endogenous control genes
PPIA and TBP were not differentially expressed in the
six B-cell subsets (p ≥ 0.05) [31]. RAG1 and RAG2, that
initiate V(D)J recombination in the BM, and are essential
for the maturation of pre-B-cells [32,33], were signifi-
cantly up-regulated in PreBI cells and PreBII cells com-
pared to the other B-cell subsets. The TF PAX5, which
is essential for early commitment to the B-cell lineage
and maintained in all B-cell subsets, except in PC [34],
was significantly up-regulated in the five B-cell subsets
compared to the PC. The TFs PRDM1, XBP1 and IRF4,
which promote and facilitate PC differentiation [12],
were significantly up-regulated in PC. In addition, IRF4
Table 2 Tissue independent yield and QC on microarray
Protocol Demographic data Array
typeTissue/B-cell subsets Sorted cells (x1000) Total no of Amp. samples Excluded Amp. yield cDNA μg Gender Age
PBMNC (F) n = 6 PreP 5 F; 1 M 49 ± 13 Exon
I 9-43 6 0 5.3 ± 0.9
N 100-130 6 2 6.5 ± 0.9
M 100-130 6 0 7.1 ± 0.6
PB 4.5-29 6 1 5.3 ± 1.3
PBMNC (F) n = 3 Lys 1 F; 2 M 43 ± 17 Exon
I 7.5 3 0 6.6 ± 1.0
N 7.5 3 0 7.1 ± 1.1
M 7.5 3 0 8.6 ± 1.5
PB 4.5-7.5 3 0 9.3 ± 0.3
PBMNC (C) n = 3 Lys Identical
I 7.5 3 0 6.0 ± 1.5
N 7.5 3 0 7.3 ± 1.1
M 7.5 3 0 6.4 ± 1.2
PB 4.5-7.5 3 1 9.8 ± 0.5
Tonsils (C) n = 8 Lys 6 F; 2 M 17 ± 10 U133
N 10-25 8 2 6.8 ± 0.8
CB 10-20 8 1 8.8 ± 0.9
CC 10-12.5 8 1 8.8 ± 0.9
M 10-20 8 2 6.7 ± 0.9
PB 5.6-20 8 1 9.3 ± 0.6
Thymus (F) n = 7 Lys 2 F; 5 M 63 ± 12 Exon
N 5-25 6 2 7.6 ± 2.2
M IgM 3.5-25 5 1 6.4 ± 3.1
M IgG 10-33 7 2 8.4 ± 3.1
PB 1-4.5 6 1 7.2 ± 4.1
BM (F) n = 7 Lys Identical
PreBI 3-25 6 0 7.8 ± 2.2
PreBII 3-25 7 1 7.8 ± 1.2
I 0.8-25 7 2 6.0 ± 1.7
N 8-25 7 0 6.3 ± 2.2
M 2-25 7 1 7.1 ± 2.5
PC 7.5-25 7 1 8.0 ± 2.2
The protocol was applied to PBMNC, tonsils, thymus and BM. The samples were sorted from either fresh (F) or cryopreserved (C) cells into PreProtect (PreP) or
lysis/binding buffer (Lys). Excluded samples were either due to failed amplification or QC on array.
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0.001) and significantly up-regulated in PreBII cells (p =
0.003) compared to I, N, and M B-cell subsets. In line
with these findings, it has been shown that IRF4 pro-
motes PreB-cell differentiation by inducing conventional
light-chain gene transcription and rearrangement [35].
Likewise, in the tonsil data set, eight evaluated genes
were expressed in accordance with the biology of lym-
phopoiesis (p-values < 0.001) [see Additional file 9]. The
genes included the formerly evaluated transcriptionfactors PAX5, PRDM1 and IRF4. In addition, four genes
(BCL6, AICDA, BACH2 and CXCR4) involved in the
GC reaction and the proliferation marker MKI67 were
included. Finally, with the implemented and validated
protocol, a gene specific B-cell atlas was generated from
the BM and tonsil tissue [see Additional files 10 and 11].
Discussion
The aim of this project was to implement and validate
the steps in a protocol for generating global GEP of
Figure 3 Biological validation. The expression values of selected genes in the B-cell subsets derived from the BM on the Exon array. Pre-B: Pre
B cells, I: immature B cells, N: naïve B cells, M: memory B cells, PC: plasma cells. *p ≥ 0.05, **p < <0.001.
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sue and blood. In the present study, we have validated a
protocol for microarray studies of minor subsets and
sorted cells from different tissues in the range 800 to
33,000 cells into lysis/binding buffer.
In order to use GEP for the analysis of populations
below 100,000 cells, RNA has to be reverse-transcribed
and amplified. The amplification technologies have been
recently evaluated with respect to reproducibility and
sensitivity and it was observed that the NuGEN protocol
was the most suitable for amplification of pico amounts of
RNA [36]. In addition, a study comparing different ampli-
fication protocols, including NuGEN protocol, Message
Amp (Ambion), Small Sample Target Labelling Assay
Version II (Affymetrix) and BioArray Small Sample
Amplification Protocol (Enzo Life Sciences) found that
all technologies performed acceptably. The NuGEN
protocol, however, resulted in the most sensitive and
specific data when 10 ng of RNA was amplified [37].
These studies were the basis for choosing the NuGEN
protocol in this study. The amplification by the
NuGEN protocol was first evaluated by comparing the
expression of eight genes in six non-amplified and
amplified CCLs. We noticed a gene-specific amplifica-
tion, meaning that some sequences or parts of tran-
scripts were amplified better than others. However,
differential gene expression was preserved across the
CCLs (r = 0.917), which is in line with previous find-
ings [21]. Next we compared the NuGEN protocol to
the standard protocol from Ambion by examining the
generated global gene expression data on the Exon
array. The reproducibility was good, both when theexpression was compared globally (r = 0.892 to 0.904)
and compared for a narrow set of genes (r = 0.950).
Correlation coefficients between methods are usually
lower than 0.90 when compared [22].
By sorting cells directly into lysis/binding buffer, a sig-
nificantly higher yield was obtained both for direct and
postponed time for preparation of mRNA purification.
The reduced yields obtained from cell storage in RNAla-
ter are very likely due to the centrifugation step intro-
duced to recover the cells prior to lysis, but do not
explain the higher Cq values of approximately 3–4 ob-
tained in PrepProtect. Of notice, reducing the centrifu-
gation force to 3000 g the same Cq values was obtained
for cells stored in PrepPretect; however, any inhibition in
the enzymatic assay has not been tested, which also may
explain the poor yield.
By using the NuGEN amplification method and MBI
technology, we obtained sufficient amplified cDNA yields
from 1,000 PB and 5,000 N B-cells to ensure successful
microarray analysis.
As the present work represents one of the first global
transcriptome studies with sorted low frequent B-cell
subsets, the reliability of the results obtained has been
considered a critical issue. Certainly, contamination of
the sorted B-cell subsets with “rosetting” non B-cells
cannot be excluded. However, it is evident from the re-
sults obtained in the present analysis that such contami-
nations do not compromise gene expression analysis.
First, the CD markers used for identification and sorting
are concordantly expressed at the transcript level [see
Additional file 5]. Secondly, biological validation of the
generated GEP was conducted in the BM and tonsil
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expressed in accordance with our knowledge of the
B-cell lymphopoiesis.Conclusion
A protocol for microarray analysis of FACS-sorted low fre-
quent B-cells was implemented and validated to achieve
new insights into B-cell differentiation. The protocol con-
sisted of CD panels for sorting early/mature and post-GC
B-cells in BM, tonsils, thymus and blood; sorting cells dir-
ectly into lysis/binding buffer; purifying mRNA by MBI;
and concentrating RNA by speedVac concentrator follow-
ing amplification with NuGEN’s technology. This protocol
represents a significant advance over established protocols
by allowing the possibility to sort the cells directly into
lysis/binding buffer, which also can be used for long-term
storage. In addition, complete CD panels for the simulta-
neous sorting of pre-GC, GC and post-GC B-cells in lymphoid
tissues and blood is provided. A gene specific B-cell
atlas was generated in BM and tonsils and a future goal
is to assign these profiles in post-GC disease classifica-
tion by “cell of origin”.Additional files
Additional file 1: Flow chart. Procedure and methods used for
establishing GEP from FACS-sorted B-cells on the Exon or U133
array. This included steps for cell sorting, cell lysis/stabilization and
storage, RNA isolation, RNA concentration and amplification for
microarray analysis. In addition, the CD marker combinations used to
distinguish between the B-cell subsets are included.
Additional file 2: Initial data analysis of quality. Table S1. Initial data
analysis of the quality and technical performance of the microarrays was
performed using the AGCC. For the tonsils on the U133 arrays, .CEL-files
were normalized with MAS5.0. Scaling factor (SF), percentage of present
calls (%P), and signal ratios of probe sets interrogating different segments
(3′/5′) were comparable across samples, with similar variation among
samples of the various B-cell subsets. For the Exon arrays, .CEL-files were
normalized with PLIER and %P was evaluated for each tissue ( PBMNC
(fresh) mean 53 ± 7; %P thymus mean 51 ± 5; %P BM mean 50 ± 6).
Further analysis was performed by evaluating the histogram and signal
box plots of the signals.
Additional file 3: Concordance between the pre-defined CD marker
and array based transcript expressions. The B-cell subsets were
divided into two groups based on the pre-defined positive or negative
CD marker. The mean and standard deviations were calculated for the
positive and negative groups based on the gene expression value for the
CD marker. Discordance was noticed if the gene expression values for a
B-cell subset in the opposite group as a pre-defined CD marker. Fisher’s
exact test for 2x2 tables was used to test for independence between the
groupings based on CD marker and GEP. Table S1. Concordance between
the pre-defined CD markers and transcript expression on array in BM.
Table S2. Concordance between the pre-defined CD markers and transcript
expression on array in PBMNC. Table S3. Concordance between the
pre-defined CD markers and transcript expression on array in thymus.
Additional file 4: Fidelity of amplification. Table S1. Six CCLs were
ranked from high to low expression and normalised to GAPDH. This
ranking was performed for both the non-amplified and the amplified
CCLs, and compared using Spearman’s rank correlation. A test for
inconsistent ranking was carried out by an exact permutation test.Additional file 5: PPIA and WHSC1 were normalised to GAPDH and
the gene expression is shown in six non-amplified and amplified
CCLs. The amplification method induces a sequence specific bias,
resulting in some sequences or parts of transcripts amplify better than
others like PPIA compared to WHSC1. However, this amplification bias for
a gene is preserved across the CCLs.
Additional file 6: Expression of selected genes between two
protocols on the Exon array. Table S1. Expression value of seven
selected genes between NuGen and the Ambion protocol on the Exon
array. RNA was extracted from the same four CCL (KMM-1, OPM-2,
SU-DHL-5 and U2932) and a 100 times less RNA was used as input in the
NuGEN protocol compared to Ambion protocol.
Additional file 7: Reproducibility between NuGEN and Ambion
protocol. Figure S1. MA plots were generated for the pair-wise comparisons
between CCLs subjected to the NuGEN and Ambion protocol. Exon array
signal values were normalized using RMA and Pearson’s correlation coefficient
was calculated using the Affymetrix Expression Console analysis package. The
log2 fold change on the y-axis (M) was plotted against the mean log2
expression on the x-axis (A).
Additional file 8: PCA plots of B-cell subsets. A-E PCA from the
gene expression data set generated from the sorted B-cell subsets.
Each dot represents a sample including PreBI dark green, PreBII salmon
pink, immature (I) light green, naive (N) blue, centroblasts (CB) light pink,
centrocytes (CC) pink, memory: (M) red; (M_IgM) light red; (M_IgG) red,
plasmablasts (PB) and plasma cells (PC) yellow. In PBMNC, cells were
either sorted within the same day as purification, depicted with a circle
(F), or cryopreserved before sorting, illustrated with a triangle (C). Each of
the B cell subpopulations is within two standard deviations from the
mean group, illustrated by the ellipses.
Additional file 9 Biological validation in tonsils on the U133 array.
Figure S1. Global GEP data generated from normal tonsil samples on the
U133 array. The box plots of eight genes are presented. N: naive B-cells,
CB: centroblasts, CC: centrocytes, M: memory B-cells, PB: plasmablasts.
*p = 0.002, **p < 0.001.
Additional file 10: Gene specific B-cell atlas in BM. Significantly
up-regulated genes in normal B-cell subsets from BM were
generated by a 2-way ANOVA model, including donor and B-cell
subsets. Up-regulated genes in each B-cell subset compared to the rest
were created (fold change > 2, FDR p-values below 0.05). The top 50 from
this list are presented in accordance to p-value. (XLSX 39 kb)
Additional file 11: Gene specific B-cell atlas in Tonsils. Significantly
up-regulated genes in normal B-cell subsets from tonsils were
generated by a 2-way ANOVA model, including donor and B-cell
subsets. Up-regulated genes in each B-cell subset compared to the rest
were created (fold change > 2, FDR p-values below 0.05). The top 50 from
this list are presented in accordance to p-value.
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